Capricor Therapeutics Inc CAPR

NAS: CAPR | ISIN: US14070B3096 30/04/2025

12,70 USD (+1,11%)

(+1,11%) 30/04/2025

Grafiek Capricor Therapeutics Inc

Grafiek Capricor Therapeutics Inc

1 dag1d 1,11%
1 week1w -4,37%
1 maand1m 34,04%
3 maanden3m -16,34%
6 maanden6m -34,70%
1 jaar1j 138,27%
5 jaar5j 74,69%

Capricor Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

10 maart 2025 · FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment · Persbericht

25 januari 2022 · Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US · Persbericht

11 maart 2021 · Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update · Persbericht

9 maart 2021 · Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform · Persbericht

1 februari 2021 · Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines · Persbericht

19 januari 2021 · Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes · Persbericht

12 januari 2021 · Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications · Persbericht

Profiel Capricor Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: capricor.com

Hoofdzetel: Beverly Hills, California Verenigde Staten

CEO: Linda Marban

Werknemers: 73

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe